Serum Level of Soluble Receptor for Advanced Glycation End Products Is Associated with A Disintegrin And Metalloproteinase 10 in Type 1 Diabetes.

Autor: Lee AC; Department of Medicine, University of Hong Kong, Hong Kong, China., Lam JK; Department of Medicine, University of Hong Kong, Hong Kong, China., Shiu SW; Department of Medicine, University of Hong Kong, Hong Kong, China., Wong Y; Department of Medicine, University of Hong Kong, Hong Kong, China., Betteridge DJ; Department of Medicine, Royal Free & University College London Medical School, London, United Kingdom., Tan KC; Department of Medicine, University of Hong Kong, Hong Kong, China.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2015 Sep 01; Vol. 10 (9), pp. e0137330. Date of Electronic Publication: 2015 Sep 01 (Print Publication: 2015).
DOI: 10.1371/journal.pone.0137330
Abstrakt: Background: The receptor for advanced glycation end products (RAGE) is involved in the pathogenesis of diabetic complications, and soluble forms of the receptor (sRAGE) can counteract the detrimental action of the full-length receptor by acting as decoy. Soluble RAGE is produced by alternative splicing [endogenous secretory RAGE (esRAGE)] and/or by proteolytic cleavage of the membrane-bound receptor. We have investigated the role of A Disintegrin And Metalloproteinase 10 (ADAM10) in the ectodomain shedding of RAGE.
Methods: Constitutive and insulin-induced shedding of RAGE in THP-1 macrophages by ADAM10 was evaluated using an ADAM10-specific metalloproteinase inhibitor. Serum ADAM10 level was measured in type 1 diabetes and control subjects, and the association with serum soluble RAGE was determined. Serum total sRAGE and esRAGE were assayed by ELISA and the difference between total sRAGE and esRAGE gave an estimated measure of soluble RAGE formed by cleavage (cRAGE).
Results: RAGE shedding (constitutive and insulin-induced) was significantly reduced after inhibition of ADAM10 in macrophages, and insulin stimulated ADAM10 expression and activity. Diabetic subjects have higher serum total sRAGE and esRAGE (p<0.01) than controls, and serum ADAM10 was also increased (p<0.01). Serum ADAM10 correlated with serum cRAGE in type 1 diabetes (r = 0.40, p<0.01) and in controls (r = 0.31. p<0.01) but no correlations were seen with esRAGE. The association remained significant after adjusting for age, gender, BMI, smoking status and HbA1c.
Conclusion: Our data suggested that ADAM10 contributed to the shedding of RAGE. Serum ADAM10 level was increased in type 1 diabetes and was a significant determinant of circulating cRAGE.
Databáze: MEDLINE
Externí odkaz: